Skip to main content
. 2021 Feb 4;11:626792. doi: 10.3389/fimmu.2020.626792

Table 3.

Effectiveness of apremilast on articular manifestations.

Baseline M3 M6 EOF
n 30 27 23 22
Complete response, n (%) 17 (63) 15 (65) 12 (55)
Partial response, n (%) 3 (11) 4 (17) 2 (9)
TJC, median [IQR] 4 [2–6] 0 [0–3] 0 [0–2] 0 [0–3]
SJC, median [IQR] 2 [1–2] 0 [0–0] 0 [0–0] 0 [0–0]

EOF, end of follow-up; IQR, interquartile range; SJC, swollen joint count; TJC, tender joint count.